SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-003572
Filing Date
2024-03-19
Accepted
2024-03-19 16:30:39
Documents
13
Period of Report
2024-03-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20240314x8k.htm   iXBRL 8-K 36084
  Complete submission text file 0001558370-24-003572.txt   155658

Data Files

Seq Description Document Type Size
2 EX-101.SCH acrs-20240314.xsd EX-101.SCH 3137
3 EX-101.LAB acrs-20240314_lab.xml EX-101.LAB 15918
4 EX-101.PRE acrs-20240314_pre.xml EX-101.PRE 10225
16 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20240314x8k_htm.xml XML 4840
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 24763868
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)